Recruitment of Black Adults into Cardiovascular Disease Trials

被引:47
作者
Prasanna, Anagha [1 ,5 ]
Miller, Hailey N. [2 ,3 ]
Wu, Yingfei [4 ]
Peeler, Anna [3 ]
Ogungbe, Oluwabunmi [3 ,5 ]
Plante, Timothy B. [6 ]
Juraschek, Stephen P. [7 ]
机构
[1] Harvard Med Sch, Boston, MA 02215 USA
[2] Duke Univ, Sch Nursing, Durham, NC USA
[3] Johns Hopkins Univ, Inst Clin & Translat Res, Baltimore, MD USA
[4] NYU Langone Hlth, New York, NY USA
[5] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA
[6] Univ Vermont, Dept Med, Larner Coll Med, Colchester, VT USA
[7] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2021年 / 10卷 / 17期
关键词
cardiovascular disease; recruitment; race and ethnicity; disparities; meta-analysis; CLINICAL-TRIALS; MINORITY; PARTICIPATION; BARRIERS; LESSONS;
D O I
10.1161/JAHA.121.021108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Although disproportionately affected by cardiovascular disease, Black adults remain underrepresented in clinical trials. The National Institutes of Health recommends that studies define goals for recruitment of underrepresented populations. However, the extent to which cardiovascular trials incorporate evidence-based recruitment strategies in their protocols is understudied. Methods and Results We systematically reviewed National Institutes of Health-funded cardiovascular clinical trials registered in ClinicalTrials.gov between 2000 and 2019. Based on publicly available or requested protocols, we focused on enrollment of Black adults as well as the following recruitment strategies: community-based, electronic medical record-based, and provider-based recruitment. A total of 100 clinical trials focused on cardiovascular disease were included in our analysis, of which 62% had published protocols, and 46% of trials had enrolled populations that were <25% Black. In our analysis of available trial protocols, 21% of trials defined a recruitment target for underrepresented groups; however, only one study reported achieving its enrollment goal. While 13% of trial protocols referenced community-based recruitment strategies, 5% explicitly mentioned involving community members in the trial design process. Defining recruitment targets was associated with higher enrollment of Black participants. Conclusions Black adults are underrepresented in National Institutes of Health-funded cardiovascular trials, and the majority of these trials did not specify a Black enrollment target, did not meet targets, and largely did not report specific plans to enroll Black adults in their studies. Future interventions should target trial design and planning phases before study initiation to address these enrollment disparities.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Evaluation of eligibility and recruitment in breast cancer clinical trials
    Lemieux, Julie
    Forget, Genevieve
    Brochu, Olyvia
    Provencher, Louise
    Cantin, Guy
    Desbiens, Christine
    Doyle, Catherine
    Poirier, Brigitte
    Camden, Stephanie
    Durocher, Martin
    BREAST, 2014, 23 (04) : 385 - 392
  • [32] Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative
    Huang, Grant D.
    Bull, Jonca
    McKee, Kelly Johnston
    Mahon, Elizabeth
    Harper, Beth
    Roberts, Jamie N.
    CONTEMPORARY CLINICAL TRIALS, 2018, 66 : 74 - 79
  • [33] Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
    Langbaum, Jessica B.
    Zissimopoulos, Julie
    Au, Rhoda
    Bose, Niranjan
    Edgar, Chris J.
    Ehrenberg, Evan
    Fillit, Howard
    Hill, Carl, V
    Hughes, Lynne
    Irizarry, Michael
    Kremen, Sarah
    Lakdawalla, Darius
    Lynn, Nancy
    Malzbender, Kristina
    Maruyama, Tetsuyuki
    Massett, Holly A.
    Patel, Deep
    Peneva, Desi
    Reiman, Eric M.
    Romero, Klaus
    Routledge, Carol
    Weiner, Michael W.
    Weninger, Stacie
    Aisen, Paul S.
    ALZHEIMERS & DEMENTIA, 2023, 19 (02) : 696 - 707
  • [34] Recruitment of African Americans to National Oncology Clinical Trials through a Clinical Trial Shared Resource
    Wujcik, Debra
    Wolff, Steven N.
    JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2010, 21 (01) : 38 - 50
  • [35] Barriers and enablers to patient recruitment for randomised controlled trials on treatment of chronic wounds: A systematic review
    Bugeja, Lyndal
    Low, Jac Kee
    McGinnes, Rosemary A.
    Team, Victoria
    Sinha, Sankar
    Weller, Carolina
    INTERNATIONAL WOUND JOURNAL, 2018, 15 (06) : 880 - 892
  • [36] Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease
    Park, Lee
    Wexler, Deborah
    CURRENT OPINION IN LIPIDOLOGY, 2010, 21 (01) : 8 - 14
  • [37] Verapamil use in patients with cardiovascular disease: An overview of randomized trials
    Pepine, CJ
    Faich, G
    Makuch, R
    CLINICAL CARDIOLOGY, 1998, 21 (09) : 633 - 641
  • [38] Effect of statin use for the primary prevention of cardiovascular disease among older adults: a cautionary tale concerning target trials emulation
    Mesidor, Miceline
    Sirois, Caroline
    Guertin, Jason Robert
    Schnitzer, Mireille E.
    Candas, Bernard
    Blais, Claudia
    Cossette, Benoit
    Poirier, Paul
    Brophy, James M.
    Lix, Lisa
    Tadrous, Mina
    Diop, Awa
    Hamel, Denis
    Talbot, Denis
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2024, 168
  • [39] Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention
    Melloni, Chiara
    Berger, Jeffrey S.
    Wang, Tracy Y.
    Gunes, Funda
    Stebbins, Amanda
    Pieper, Karen S.
    Dolor, Rowena J.
    Douglas, Pamela S.
    Mark, Daniel B.
    Newby, L. Kristin
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (02): : 135 - 142
  • [40] Antioxidants in cardiovascular disease: Randomized trials
    Gaziano, JM
    NUTRITION, 1996, 12 (09) : 583 - 588